Myeloma
If it’s your first time on this website, please read the disclaimer section.
May 25 – Jun 01, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
SCI TRANSL MED · Q1 JOURNAL - RANK #3/195TOP-TIER
Part A of a phase 1 trial (NCT04318327) prospectively evaluated durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T therapy, in 55 patients with relapsed/refractory multiple myeloma with safety as the primary objective and efficacy/feasibility as secondary endpoints. Patients received a single infusion at one of four flat target doses after a median 24-day vein-to-vein time. The overall response rate was 98%, stringent complete response rate 55%, and minimal residual disease negativity 80% among evaluable patients (35/44); no unexpected safety findings or delayed neurotoxicity were observed. Immunophenotyping/transcriptomics showed a preserved stem-like phenotype, supporting initiation of a phase 2 trial (NCT05172596).
10.1126/scitranslmed.adx1799
May 18 – May 25, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.
CANCER-AM CANCER SOC · Q1 JOURNAL - RANK #68/326
Elranatamab was evaluated for efficacy and safety in relapsed or refractory multiple myeloma within a U.S. subgroup from the prospective MagnetisMM-3 trial (NCT04649359). In this post hoc analysis, 47 BCMA-naive patients received 76 mg of elranatamab weekly, followed by less frequent dosing upon durable responses. At a median follow-up of 39.6 months, the objective response rate was 66.0% (95% CI, 50.7-79.1); 42.6% (95% CI, 28.3-57.8) achieved complete response or better, median duration of response was 40.8 months (24.0-not estimable [NE]), progression-free survival was 27.3 months (4.3-NE), and overall survival was 43.6 months (14.9-NE). The results indicate elranatamab’s durable efficacy and acceptable safety in a heavily pretreated population, consistent with the overall MagnetisMM-3 BCMA-naive group.
10.1002/cncr.70442
Apr 20 – Apr 27, 2026
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1, single-arm, open-label trial evaluated the safety and efficacy of ESO-T01, an in vivo anti-BCMA CAR-T cell therapy, in five heavily pretreated adults with relapsed or refractory multiple myeloma. Patients received a single intravenous infusion of 0.2 × 10^10 transduction units without prior lymphodepletion, with a median follow-up of 6.0 months. Four of five patients achieved objective responses (three stringent complete remissions), with minimal residual disease negativity (10^-6) in all evaluable responders by day 60, though all experienced grade 3+ adverse events, including cytokine release syndrome (4/5) and one treatment-related death. The study demonstrates preliminary feasibility and safety of in vivo CAR-T generation but was halted early in 2025 due to safety concerns.
10.1038/s41591-026-04244-6
Mar 30 – Apr 06, 2026
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.
LANCET HAEMATOL · Q1 JOURNAL - RANK #3/98TOP-TIER
This randomized, open-label, phase 3 superiority trial (ATLAS) compared carfilzomib-lenalidomide-dexamethasone (KRd) maintenance therapy with lenalidomide (R) alone in 180 patients with newly diagnosed multiple myeloma after autologous hematopoietic stem-cell transplantation. At a median follow-up of 69 months, the 4-year progression-free survival was 67.5% (95% CI 56.2–76.4) in the KRd group versus 38.0% (27.6–48.2) in the R group (hazard ratio 0.46, 95% CI 0.30–0.70; log-rank p=0.0002). The study concluded that KRd demonstrated enhanced efficacy compared to lenalidomide alone, supporting strategies for maintenance therapy intensification post-transplant. The trial was funded by Amgen and Celgene (Bristol Myers Squibb).
10.1016/S2352-3026(26)00011-6